Drug-Coated Balloons for Coronary and Peripheral Interventional Procedures

  title={Drug-Coated Balloons for Coronary and Peripheral Interventional Procedures},
  author={Jochen W{\"o}hrle},
  journal={Current Cardiology Reports},
  • J. Wöhrle
  • Published 24 July 2012
  • Medicine
  • Current Cardiology Reports
Paclitaxel-coated balloon (PCB) angioplasty reduces neointimal proliferation, restenosis, and clinical need for target lesion revascularization (TLR). PCB was superior for coronary restenosis in bare-metal and drug-eluting stents compared with uncoated balloon angioplasty and was noninferior compared with paclitaxel-eluting stents. PCB angioplasty should be considered for treatment of coronary in-stent restenosis. For de novo lesions, PCB plus endothelial progenitor cell capturing stents… 
Advances in Percutaneous Therapies for Peripheral Artery Disease: Drug-Coated Balloons
Drug-coated balloons produce better outcomes than percutaneous transluminal angioplasty alone in de novo and in-stent restenosis lesions of superficial femoral artery and popliteal arteries.
Usage of drug-coated balloon in acute ST-segment elevation myocardial infarction?!
The paclitaxel DCB is an emerging device in percutaneous coronary intervention and can be safely used in selected cases where stent implantation could be associated with increasedrisk of complications (i.e. increased risk of GI bleeding).
Drug-Eluting Balloons in the Treatment of Coronary De Novo Lesions: A Comprehensive Review
The main indication for DEB seems to be small vessel disease, especially in clinical scenarios in which a contraindication to dual antiplatelet therapy exists, so larger randomized controlled studies with prolonged follow-up comparing DEB with best in class DES are warranted.
In vitro evaluation of paclitaxel coatings for delivery via drug-coated balloons.
  • Wiebke Kempin, S. Kaule, A. Seidlitz
  • Medicine
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
  • 2015
The Eternal Tale of Dialysis Access Vessels and Restenosis: Are Drug-Eluting Balloons the Solution?
The technique of drug-eluting balloon (DEB) angioplasty has shown promising results in the treatment of femoropopliteal arteriosclerotic lesions, but general recommendations regarding the value of DEBs in dialysis access vessels cannot be considered as serious unless large randomized controlled trials have been performed.
Paclitaxel Drug-eluting Balloons to Recurrent In-stent Stenoses in Autogenous Dialysis Fistulas: A Retrospective Study
It is suggested that DEBs significantly reduce re-intervention on recurrent in-stent AVF stenoses in autogenous dialysis arteriovenous fistulas, and this retrospective study suggests that this is the case.
A Multilayer Functionalized Drug-Eluting Balloon for Treatment of Coronary Artery Disease
A functional DEB platform with such a multilayer coating approach would be widely utilized for percutaneous coronary intervention (PCI), and ex vivo experiments demonstrated efficient drug transfer of approximately 65% in the presence of the 1st layer, to the tissue in 60 s after treatment.
Drug Coated Balloon Angioplasty vs. Standard Percutaneous Transluminal Angioplasty in Below the Knee Peripheral Arterial Disease: A Systematic Review and Meta-Analysis.
Local drug delivery to prevent restenosis.
This review has summarised the most important aspects and clinical studies on bifurcation lesion treatment with the aim to give the readers a practical approach to b ifurcation PCI.


Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO Study
Dior PCB failed to show equivalence to Taxus DES regarding angiographic end points during PCI of small coronary arteries and was compared to one of the most widely used DES.
Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of Restenosis
Paclitaxel balloon coating is safe, and it effectively inhibits restenosis after coronary angioplasty with stent implantation in the porcine model, and the degree of reduction in neointimal formation was comparable to that achieved with drug-eluting stents.
Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial.
Treatment of bare-metal in-stent restenotic lesions with paclitaxel-eluting stents rather than angioplasty followed by VBT reduces clinical and angiographic restenosis at 9 months and improves event-free survival.
Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg.
Use of paclitaxel-coated angioplasty balloons during percutaneous treatment of femoropopliteal disease is associated with significant reductions in late lumen loss and target-lesion revascularization and no significant benefit is seen with the use of a paclitxel-containing contrast medium.
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
As compared with bare-metal stents, the slow-release, polymer-based, paclitaxel-eluting stent is safe and markedly reduces the rates of clinical and angiographic restenosis at nine months.
Treatment of coronary in-stent restenosis with a novel paclitaxel urea coated balloon.
The results of this first-in-human series with a pac litaxel urea coated balloon are comparable to paclitaxel iopromide coated balloon catheters, and randomized, controlled clinical trials are warranted to further evaluate this promising approach.
Drug-eluting balloon: very short-term exposure and overlapping.
DEB were found to effectively reduce neointimal proliferation regardless of inflation time and dose within the tested range and no adverse reactions were seen as dose was increased to more than three times the clinically tested dose.
Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis
Treatment of coronary in-stent restenosis with thepaclitaxel-coated balloon was at least as efficacious and as well tolerated as the paclitaxe-eluting stent, and inhibition of re-restenosis does not require a second stent implantation.
Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus.
  • R. Ali, R. Degenhardt, M. Unverdorben
  • Medicine
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
  • 2011
The clinical and angiographic outcome of the combination of the drug-eluting balloon SeQuent Please with a cobalt chromium stent compared to the drug eluting Taxus stent are similar.